BioNTech SE (BNTX)

[Man6677]

H.C. Wainwright Thinks BioNTech SE’s Stock is Going to Recover

Source: TipRanks
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $298.00. The company's shares closed last Tuesday at $159.80, close to its 52-week low of $121.32. According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of -29.6% and a 17.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics. Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $243.30, a 57.4% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-biontech-ses-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral

BNTX $$$$$$